The two deals will support the clinical and commercial supply of PNT2002, a radiopharmaceutical candidate for the treatment of metastatic castrate-resistant prostate cancer. The first contract details a partnership for the clinical development of PNT2002, while the second is a long-term commercial agreement for the supply of no-carrier-added lutetium-177 following the marketing approval of PNT2002.
A phase III clinical trial for PNT2002 is expected to begin enrolling patients in the fourth quarter, according to the companies. Further terms of the deals were not disclosed.
Copyright © 2020 AuntMinnieEurope.com